Results 161 to 170 of about 49,735 (302)

Pan-Neurofascin Antibody-Associated Nodopathy: A Critical Guillain-Barré Syndrome Mimic in the Differential Diagnosis-Report of Two Cases. [PDF]

Case Rep Crit Care
Nemethova A, De Ridder W, Baar I, Alonso-Jimenez A.   +3 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis. [PDF]

Front Immunol
Jiang Q, Gu Z.
europepmc   +1 more source

IVIG and ciclosporin for Kawasaki disease [PDF]

Nature Reviews Rheumatology, 2019
openaire   +2 more sources

Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.

, 1998
Therapeutic preparations of normal human IgG for i.v. use (IVIg) exhibit a broad spectrum of immunoregulatory activities in vitro and in vivo. IVIg has been shown to inhibit the proliferation of activated B and T lymphocytes and of several autonomously ...
Prasad NK, Zeuner A, Papoff G, Bonnin E, Ruberti G, Kaveri SV, Kazatchkine MD   +6 more
core  

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Post-IVIG Aseptic Meningitis in a Pediatric Patient With Kawasaki Disease: A Case Report. [PDF]

Cureus
Kheir S, Elouali A, Sara A, Rkain M, Babakhouya A.   +4 more
europepmc   +1 more source

Unraveling the IVIG mystique [PDF]

Transfusion, 2013
openaire   +2 more sources

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Impact of Gut Microbiota Dysbiosis in Treatment Outcomes of Guillain-Barré Syndrome. [PDF]

J Peripher Nerv Syst
Hayat S, Nayeem MAJ, Asad A, Mostafa MG, Begum R, Munni MA, Anjuman AA, Sadia SA, Upama IJ, Hasan I, Mohammad QD, Islam Z.   +11 more
europepmc   +1 more source